Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules
- PMID: 18940221
- DOI: 10.1016/j.vaccine.2008.10.003
Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules
Abstract
Two paediatric tick-borne encephalitis vaccines, Encepur Children and FSME-IMMUN Junior, are used widely in Europe. This study compared the immunogenicity and safety of both vaccines, administered using the conventional (Days 0, 28, and 300) or accelerated (Days 0, 14, and 300) schedule and evaluated whether a third dose of Encepur Children can complete a primary vaccination course initiated with FSME-IMMUN Junior. A total of 334 children 1 to < 11 years of age were enrolled in this Phase IV randomized, controlled, single-blind, multi-centre trial. All subjects, irrespective of study arm, received Encepur Children as the third dose on Day 300. The percentage of subjects with antibody titres > or = 10, as determined by neutralization test (NT), was assessed and local and systemic reactions were monitored and solicited. Within both the conventional and accelerated schedules, the proportion of subjects achieving an NT > or = 10 was higher in the group that received Encepur Children, compared with the group that received FSME-IMMUN Junior, at Days 42 and 300 (conventional schedule Day 300, P < 0.001 Encepur Children versus FSME-IMMUN Junior; accelerated schedule Days 42 and 300, P<0.001 Encepur Children versus FSME-IMMUN Junior). The third dose of Encepur Children led to a substantial increase in the proportion of subjects in the FSME-IMMUN Junior groups achieving NT > or = 10. Overall, >95% of all children achieved NT > or = 10, on completion of the primary vaccination course. Encepur Children provides an immune response, measured by neutralizing TBE antibodies, that is superior to FSME-IMMUN Junior and can successfully be used to complete a primary vaccination course initiated with FSME-IMMUN Junior. Both vaccines were well tolerated, with comparable safety profiles; no vaccine-related serious adverse events were reported.
Similar articles
-
Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.Hum Vaccin Immunother. 2014;10(10):2819-33. doi: 10.4161/hv.29984. Hum Vaccin Immunother. 2014. PMID: 25483679 Free PMC article. Review.
-
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior.Hum Vaccin Immunother. 2012 Jun;8(6):736-42. doi: 10.4161/hv.20058. Epub 2012 Jun 1. Hum Vaccin Immunother. 2012. PMID: 22699436 Clinical Trial.
-
Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme.Vaccine. 2011 Oct 6;29(43):7307-19. doi: 10.1016/j.vaccine.2011.07.089. Epub 2011 Aug 16. Vaccine. 2011. PMID: 21843576 Review.
-
Comparison of immunogenicity and safety between two paediatric TBE vaccines.Vaccine. 2010 Jun 23;28(29):4680-5. doi: 10.1016/j.vaccine.2010.04.047. Epub 2010 Apr 28. Vaccine. 2010. PMID: 20433803 Clinical Trial.
-
Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.Vaccine. 2006 Jun 12;24(24):5256-63. doi: 10.1016/j.vaccine.2006.03.061. Epub 2006 Apr 3. Vaccine. 2006. PMID: 16624457 Clinical Trial.
Cited by
-
Defining the "Correlate(s) of Protection" to tick-borne encephalitis vaccination and infection - key points and outstanding questions.Front Immunol. 2024 Jan 22;15:1352720. doi: 10.3389/fimmu.2024.1352720. eCollection 2024. Front Immunol. 2024. PMID: 38318179 Free PMC article. Review.
-
Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.MMWR Recomm Rep. 2023 Nov 10;72(5):1-29. doi: 10.15585/mmwr.rr7205a1. MMWR Recomm Rep. 2023. PMID: 37943707 Free PMC article.
-
Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go.Microorganisms. 2022 Feb 18;10(2):464. doi: 10.3390/microorganisms10020464. Microorganisms. 2022. PMID: 35208918 Free PMC article. Review.
-
The envelope protein of tick-borne encephalitis virus influences neuron entry, pathogenicity, and vaccine protection.J Neuroinflammation. 2020 Sep 28;17(1):284. doi: 10.1186/s12974-020-01943-w. J Neuroinflammation. 2020. PMID: 32988388 Free PMC article.
-
Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules".Hum Vaccin Immunother. 2020 Sep 1;16(9):2282-2284. doi: 10.1080/21645515.2020.1798713. Epub 2020 Aug 18. Hum Vaccin Immunother. 2020. PMID: 32810427 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials